Genovis AB (GENO) – Company Profile and SWOT Analysis

Genovis AB (GENO) – Company Profile & SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Key Highlights

Genovis AB (Genovis) develops, produces, and markets enzyme products, which facilitate the development and quality control of biological drugs. Genovis offers an array of products, including 25 enzymes in different product formats under the SmartEnzymes brand, and technologies related to antibody labeling and remodeling of antibody glycans. Its SmartEnzymes product portfolio encompasses Fabricator (IdeS), Gingiskhan (KGP), Fabulous (SpeB), Glycinator (EndoS49), Fabricator Z (IdeZ), Gingisrex (Rgp) and IgGzero (EndoS). The company’s products are used for antibody molecules analysis to identify and characterize proteins, antibody-based biotherapeutics; monoclonal antibodies, antibody drug conjugates and biosimilars. The company has an operational presence in Europe, North America, and Asia. Genovis is headquartered in Kavlinge, Sweden.

Scope

• Detailed information on Genovis AB required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Genovis AB in the form of a SWOT analysis

• An in-depth view of the business model of Genovis AB including a breakdown and examination of key business segments

• News about Genovis AB, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Genovis AB and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Genovis AB as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Genovis ABs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Thermo Fisher Scientific Inc

Abcam Ltd

Santa Cruz Biotechnology Inc

Bio-Rad Laboratories Inc

Global Life Sciences Solutions USA LLC

New England Biolabs Inc

Agilent Technologies Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Genovis AB - Key Facts

Genovis AB - Key Employees

Genovis AB - Key Employee Biographies

Genovis AB - Major Products and Services

Genovis AB - History

Genovis AB - Company Statement

Genovis AB - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Genovis AB - Business Description

Product Category: Antibodies

Performance

Product Category: Enzyme

Performance

Geographical Segment: Other Countries

Performance

Geographical Segment: Sweden

Performance

R&D Overview

Genovis AB - Corporate Strategy

Genovis AB - SWOT Analysis

SWOT Analysis - Overview

Genovis AB - Strengths

Genovis AB - Weaknesses

Genovis AB - Opportunities

Genovis AB - Threats

Genovis AB - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Genovis AB, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024

Genovis AB, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024

Genovis AB, Recent Deals Summary

Section 5 – Company’s Recent Developments

Sep 23, 2024: Genovis Launches FabRICATOR Xtra: Next-Generation Enzyme for Future Antibody Therapeutics

May 15, 2024: Genovis Announces Interim Report January - March 2024

Apr 24, 2024: Genovis Annual Report 2023 Published

Feb 15, 2024: Genovis : Year-end report January-December 2023

Aug 24, 2023: Genovis : Half-Yearly Report January-June 2023

Jun 02, 2023: Genovis Launch Innovative Igm-Specific Protease With Wide-Ranging Applications in Life Science Markets

May 16, 2023: Genovis announces interim report January-March 2023

May 16, 2023: Genovis Announces Annual General Meeting May 16, 2023

Apr 25, 2023: Genovis announces annual results 2022

Apr 11, 2023: Genovis Notice Convening the 2023 Annual General Meeting

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Genovis AB, Key Facts

Genovis AB, Key Employees

Genovis AB, Key Employee Biographies

Genovis AB, Major Products and Services

Genovis AB, History

Genovis AB, Subsidiaries

Genovis AB, Key Competitors

Genovis AB, Ratios based on current share price

Genovis AB, Annual Ratios

Genovis AB, Annual Ratios (Cont…1)

Genovis AB, Annual Ratios (Cont…2)

Genovis AB, Interim Ratios

Genovis AB, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024

Genovis AB, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024

Genovis AB, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Genovis AB, Performance Chart (2019 – 2023)

Genovis AB, Ratio Charts

Genovis AB, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024

Genovis AB, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

    Pricing

Quick Buy
Add to basket Enquire before buying

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports